Edoxaban to prevent catheter-related blood clots in cancer patients
Treatments studied
Part of Cancer, Heart & circulation clinical trials.
This trial tests whether a daily pill called edoxaban can prevent blood clots that sometimes form around a central venous catheter in people with cancer. If it works, it could lower the risk of a dangerous clot without major side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a cancer diagnosis and have a central line (a tube placed in a large vein) for treatment.
- Your score on a special test predicts a higher chance of developing a catheter-related blood clot.
- You are generally able to care for yourself (ECOG score 0-2).
- Your doctor expects you to live at least 6 more months.
- You are not pregnant or breastfeeding.
- You have not had a blood clot in your legs or lungs in the last 3 months.
- You are not currently taking other blood thinners (unless just to keep your catheter open).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
This trial tests whether continuing a lower dose of blood thinners can prevent another blood clot in cancer patients who have had a clot in an arm or chest catheter. It may help find a safer way to prevent future clots.
This trial studies the safety of managing blood thinners (like apixaban or warfarin) around the time of cancer surgery or procedures. It aims to help doctors understand how to best handle these medications to reduce risks.
This trial tests different ways to take the blood thinner apixaban to prevent blood clots in people with cancer who are starting or switching their cancer treatment. It aims to find the best dose for safety and effectiveness.
This study tests a plan for how cancer patients taking blood thinners (called DOACs) should handle their medication before and after getting a central line (a special IV tube placed in a large vein for treatments). The goal is to find a safe way to prepare for the procedure without increasing the risk of bleeding or blood clots.
This study compares two blood-thinning medications, edoxaban and apixaban, in people who have both cancer and a blood clot. The goal is to see which one works better and is safer for preventing another clot while treating your cancer.
Hear when a new Thrombosis, Venous trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.